| Smallpox and mpox (orthopoxviruses): WHO position paper | World Health Organization (WHO) | 2024 | Guidance | Anglais, Français |
| Summary of WHO SAGE recommendations for mpox vaccines, including considerations for off-label use | World Health Organization (WHO) | 2025 | Presentation | Anglais |
| Off-label vaccine use: explanatory note for countries | World Health Organization (WHO) | 2024 | Guidance | Anglais |
| MVA-BN (Modified Vaccinia Ankara – Bavarian Nordic) smallpox and mpox vaccine: Interim guidance | World Health Organization (WHO) | 2024 | Guidance | Anglais, Français |
| ETF statement on the use of Imvanex for the prevention of mpox in children below 12 years of age | European Medicines Agency | 2024 | Guidance | Anglais |
| Regulatory & Policy Considerations for Mpox Vaccines in African Countries | World Health Organization (WHO), European Medicines Agency, Bavarian Nordic | 2025 | Presentation | Anglais |
| LC16m8 (live-attenuated freeze-dried vaccinia) smallpox and mpox vaccine - Interim Guidance | World Health Organization (WHO) | 2025 | Guidance | Anglais, Français |
| Frequently Asked Questions (FAQ) on use of fractional dosing with intradermal administration of mpox MVA-BN vaccine in the context of vaccine supply-constrained outbreak response | World Health Organization (WHO) | 2025 | Guidance | Anglais |
